[{"edinetCode":"E00919","endDate":"2017\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":29900.0,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":243861000.0,"sharesOwendPercent":0.3085,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":null,"currentAssets":null,"fixedAsset":null,"tangibleFixedAssets":null,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":null,"currentLiabilities":null,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":null,"capitalSurplus":null,"accumulatedEarnings":null,"treasuryStock":null,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":null,"costOfSales":null,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":35.5,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"asr","submitDate":"2017\/6\/29","stockCode":4502,"accountingYear":"第140期(自　2016年４月１日　至　2017年３月31日)","accountingYearStart":"2016\/4\/1","accountingYearEnd":"2017\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00919","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":77923,"settlementDate":"2022\/3\/31","submitterName":"武田薬品工業株式会社","submitterNameEnglish":"Takeda Pharmaceutical Company Limited","submitterNameKana":"タケダヤクヒンコウギョウカブシキカイシャ","location":"大阪市中央区道修町四丁目１番１号","industory":"医薬品","corporateNumber":2120000000000.0},{"edinetCode":"E00919","endDate":"2018\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":27230.0,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":241309000.0,"sharesOwendPercent":0.3037,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":null,"currentAssets":null,"fixedAsset":null,"tangibleFixedAssets":null,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":null,"currentLiabilities":null,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":null,"capitalSurplus":null,"accumulatedEarnings":null,"treasuryStock":null,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":null,"costOfSales":null,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":21.7,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"asr","submitDate":"2018\/6\/28","stockCode":4502,"accountingYear":"第141期(自　2017年４月１日　至　2018年３月31日)","accountingYearStart":"2017\/4\/1","accountingYearEnd":"2018\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00919","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":77923,"settlementDate":"2022\/3\/31","submitterName":"武田薬品工業株式会社","submitterNameEnglish":"Takeda Pharmaceutical Company Limited","submitterNameKana":"タケダヤクヒンコウギョウカブシキカイシャ","location":"大阪市中央区道修町四丁目１番１号","industory":"医薬品","corporateNumber":2120000000000.0},{"edinetCode":"E00919","endDate":"2019\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":49578.0,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":511183000.0,"sharesOwendPercent":0.3266,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":13872300000000.0,"currentAssets":3050660000000.0,"fixedAsset":null,"tangibleFixedAssets":1316530000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":8708730000000.0,"currentLiabilities":2510930000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":1643590000000.0,"capitalSurplus":1650230000000.0,"accumulatedEarnings":1569370000000.0,"treasuryStock":-57142000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":null,"costOfSales":659690000000.0,"grossProfit":null,"sgaExpenses":717599000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":39.8,"roe":null,"cashFlowFromOperatingActivities":328479000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":-2835700000000.0,"cashFlowFromFinancialActivities":2946240000000.0,"changesInCashAndCashEquivalents":null,"列1":"asr","submitDate":"2019\/6\/27","stockCode":4502,"accountingYear":"第142期(自　2018年４月１日　至　2019年３月31日)","accountingYearStart":"2018\/4\/1","accountingYearEnd":"2019\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00919","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":77923,"settlementDate":"2022\/3\/31","submitterName":"武田薬品工業株式会社","submitterNameEnglish":"Takeda Pharmaceutical Company Limited","submitterNameKana":"タケダヤクヒンコウギョウカブシキカイシャ","location":"大阪市中央区道修町四丁目１番１号","industory":"医薬品","corporateNumber":2120000000000.0},{"edinetCode":"E00919","endDate":"2019\/6\/30","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":13550400000000.0,"currentAssets":2932160000000.0,"fixedAsset":null,"tangibleFixedAssets":1481110000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":8675970000000.0,"currentLiabilities":2006620000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":1668090000000.0,"capitalSurplus":1658110000000.0,"accumulatedEarnings":1405030000000.0,"treasuryStock":-84895000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":300592000000.0,"grossProfit":null,"sgaExpenses":239213000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":120789000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":-41603000000.0,"cashFlowFromFinancialActivities":-177700000000.0,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2019\/8\/9","stockCode":4502,"accountingYear":null,"accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00919","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":77923,"settlementDate":"2022\/3\/31","submitterName":"武田薬品工業株式会社","submitterNameEnglish":"Takeda Pharmaceutical Company Limited","submitterNameKana":"タケダヤクヒンコウギョウカブシキカイシャ","location":"大阪市中央区道修町四丁目１番１号","industory":"医薬品","corporateNumber":2120000000000.0},{"edinetCode":"E00919","endDate":"2019\/12\/31","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":13031500000000.0,"currentAssets":2520330000000.0,"fixedAsset":null,"tangibleFixedAssets":1468840000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":8155280000000.0,"currentLiabilities":2127370000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":1668090000000.0,"capitalSurplus":1673730000000.0,"accumulatedEarnings":1378450000000.0,"treasuryStock":-87478000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":841583000000.0,"grossProfit":null,"sgaExpenses":711679000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":484315000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":255874000000.0,"cashFlowFromFinancialActivities":-861282000000.0,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2020\/2\/13","stockCode":4502,"accountingYear":null,"accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00919","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":77923,"settlementDate":"2022\/3\/31","submitterName":"武田薬品工業株式会社","submitterNameEnglish":"Takeda Pharmaceutical Company Limited","submitterNameKana":"タケダヤクヒンコウギョウカブシキカイシャ","location":"大阪市中央区道修町四丁目１番１号","industory":"医薬品","corporateNumber":2120000000000.0},{"edinetCode":"E00919","endDate":"2020\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":47495.0,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":505304000.0,"sharesOwendPercent":0.3206,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":12821100000000.0,"currentAssets":2469430000000.0,"fixedAsset":null,"tangibleFixedAssets":1386370000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":8093610000000.0,"currentLiabilities":2175900000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":1668120000000.0,"capitalSurplus":1680290000000.0,"accumulatedEarnings":1369970000000.0,"treasuryStock":-87463000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":null,"costOfSales":1089760000000.0,"grossProfit":null,"sgaExpenses":964737000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":116.4,"roe":null,"cashFlowFromOperatingActivities":669752000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":292119000000.0,"cashFlowFromFinancialActivities":-1005210000000.0,"changesInCashAndCashEquivalents":null,"列1":"asr","submitDate":"2020\/6\/24","stockCode":4502,"accountingYear":"第143期(自　2019年４月１日　至　2020年３月31日)","accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00919","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":77923,"settlementDate":"2022\/3\/31","submitterName":"武田薬品工業株式会社","submitterNameEnglish":"Takeda Pharmaceutical Company Limited","submitterNameKana":"タケダヤクヒンコウギョウカブシキカイシャ","location":"大阪市中央区道修町四丁目１番１号","industory":"医薬品","corporateNumber":2120000000000.0},{"edinetCode":"E00919","endDate":"2020\/6\/30","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":12613900000000.0,"currentAssets":2474760000000.0,"fixedAsset":null,"tangibleFixedAssets":1366180000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":7923090000000.0,"currentLiabilities":2031540000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":1668150000000.0,"capitalSurplus":1661470000000.0,"accumulatedEarnings":1330050000000.0,"treasuryStock":-60717000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":238078000000.0,"grossProfit":null,"sgaExpenses":202374000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":145861000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":662000000.0,"cashFlowFromFinancialActivities":-192765000000.0,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2020\/8\/12","stockCode":4502,"accountingYear":null,"accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00919","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":77923,"settlementDate":"2022\/3\/31","submitterName":"武田薬品工業株式会社","submitterNameEnglish":"Takeda Pharmaceutical Company Limited","submitterNameKana":"タケダヤクヒンコウギョウカブシキカイシャ","location":"大阪市中央区道修町四丁目１番１号","industory":"医薬品","corporateNumber":2120000000000.0},{"edinetCode":"E00919","endDate":"2020\/9\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":506345000.0,"sharesOwendPercent":0.3212,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":12414700000000.0,"currentAssets":2585140000000.0,"fixedAsset":null,"tangibleFixedAssets":1366950000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":7748250000000.0,"currentLiabilities":1709660000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":1668150000000.0,"capitalSurplus":1668870000000.0,"accumulatedEarnings":1337070000000.0,"treasuryStock":-59565000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":487720000000.0,"grossProfit":null,"sgaExpenses":418631000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":392011000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":28224000000.0,"cashFlowFromFinancialActivities":-418210000000.0,"changesInCashAndCashEquivalents":null,"列1":"q2r","submitDate":"2020\/11\/10","stockCode":4502,"accountingYear":null,"accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00919","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":77923,"settlementDate":"2022\/3\/31","submitterName":"武田薬品工業株式会社","submitterNameEnglish":"Takeda Pharmaceutical Company Limited","submitterNameKana":"タケダヤクヒンコウギョウカブシキカイシャ","location":"大阪市中央区道修町四丁目１番１号","industory":"医薬品","corporateNumber":2120000000000.0},{"edinetCode":"E00919","endDate":"2020\/12\/31","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":12286100000000.0,"currentAssets":2616600000000.0,"fixedAsset":null,"tangibleFixedAssets":1363140000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":7646710000000.0,"currentLiabilities":1804960000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":1668150000000.0,"capitalSurplus":1678660000000.0,"accumulatedEarnings":1306570000000.0,"treasuryStock":-59567000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":740862000000.0,"grossProfit":null,"sgaExpenses":641275000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":609971000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":100199000000.0,"cashFlowFromFinancialActivities":-718282000000.0,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2021\/2\/12","stockCode":4502,"accountingYear":null,"accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00919","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":77923,"settlementDate":"2022\/3\/31","submitterName":"武田薬品工業株式会社","submitterNameEnglish":"Takeda Pharmaceutical Company Limited","submitterNameKana":"タケダヤクヒンコウギョウカブシキカイシャ","location":"大阪市中央区道修町四丁目１番１号","industory":"医薬品","corporateNumber":2120000000000.0},{"edinetCode":"E00919","endDate":"2021\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":47099.0,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":484418000.0,"sharesOwendPercent":0.3073,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":12912300000000.0,"currentAssets":2712890000000.0,"fixedAsset":null,"tangibleFixedAssets":1453920000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":7735120000000.0,"currentLiabilities":1773180000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":1668150000000.0,"capitalSurplus":1688420000000.0,"accumulatedEarnings":1509910000000.0,"treasuryStock":-59552000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":null,"costOfSales":994308000000.0,"grossProfit":null,"sgaExpenses":875663000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":16.6,"roe":null,"cashFlowFromOperatingActivities":1010930000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":393530000000.0,"cashFlowFromFinancialActivities":-1088350000000.0,"changesInCashAndCashEquivalents":null,"列1":"asr","submitDate":"2021\/6\/29","stockCode":4502,"accountingYear":"第144期(自　2020年４月１日　至　2021年３月31日)","accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00919","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":77923,"settlementDate":"2022\/3\/31","submitterName":"武田薬品工業株式会社","submitterNameEnglish":"Takeda Pharmaceutical Company Limited","submitterNameKana":"タケダヤクヒンコウギョウカブシキカイシャ","location":"大阪市中央区道修町四丁目１番１号","industory":"医薬品","corporateNumber":2120000000000.0},{"edinetCode":"E00919","endDate":"2021\/6\/30","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":12657200000000.0,"currentAssets":2476460000000.0,"fixedAsset":null,"tangibleFixedAssets":1452170000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":7418590000000.0,"currentLiabilities":1706780000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":1669130000000.0,"capitalSurplus":1682500000000.0,"accumulatedEarnings":1503810000000.0,"treasuryStock":-42344000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":241264000000.0,"grossProfit":null,"sgaExpenses":219843000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":166858000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":-70445000000.0,"cashFlowFromFinancialActivities":-411038000000.0,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2021\/8\/6","stockCode":4502,"accountingYear":null,"accountingYearStart":"2021\/4\/1","accountingYearEnd":"2022\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00919","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":77923,"settlementDate":"2022\/3\/31","submitterName":"武田薬品工業株式会社","submitterNameEnglish":"Takeda Pharmaceutical Company Limited","submitterNameKana":"タケダヤクヒンコウギョウカブシキカイシャ","location":"大阪市中央区道修町四丁目１番１号","industory":"医薬品","corporateNumber":2120000000000.0},{"edinetCode":"E00919","endDate":"2021\/9\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":554952000.0,"sharesOwendPercent":0.3508,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":12560300000000.0,"currentAssets":2456350000000.0,"fixedAsset":null,"tangibleFixedAssets":1459920000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":7235910000000.0,"currentLiabilities":1918750000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":1676260000000.0,"capitalSurplus":1686490000000.0,"accumulatedEarnings":1551150000000.0,"treasuryStock":-41037000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":517061000000.0,"grossProfit":null,"sgaExpenses":431854000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":400011000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":-103349000000.0,"cashFlowFromFinancialActivities":-658405000000.0,"changesInCashAndCashEquivalents":null,"列1":"q2r","submitDate":"2021\/11\/5","stockCode":4502,"accountingYear":null,"accountingYearStart":"2021\/4\/1","accountingYearEnd":"2022\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00919","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":77923,"settlementDate":"2022\/3\/31","submitterName":"武田薬品工業株式会社","submitterNameEnglish":"Takeda Pharmaceutical Company Limited","submitterNameKana":"タケダヤクヒンコウギョウカブシキカイシャ","location":"大阪市中央区道修町四丁目１番１号","industory":"医薬品","corporateNumber":2120000000000.0},{"edinetCode":"E00919","endDate":"2021\/12\/31","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":12698500000000.0,"currentAssets":2477890000000.0,"fixedAsset":null,"tangibleFixedAssets":1493590000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":7366700000000.0,"currentLiabilities":1809250000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":1676260000000.0,"capitalSurplus":1697560000000.0,"accumulatedEarnings":1466930000000.0,"treasuryStock":-91013000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":798466000000.0,"grossProfit":null,"sgaExpenses":662932000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":747521000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":-172487000000.0,"cashFlowFromFinancialActivities":-826465000000.0,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2022\/2\/10","stockCode":4502,"accountingYear":null,"accountingYearStart":"2021\/4\/1","accountingYearEnd":"2022\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00919","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":77923,"settlementDate":"2022\/3\/31","submitterName":"武田薬品工業株式会社","submitterNameEnglish":"Takeda Pharmaceutical Company Limited","submitterNameKana":"タケダヤクヒンコウギョウカブシキカイシャ","location":"大阪市中央区道修町四丁目１番１号","industory":"医薬品","corporateNumber":2120000000000.0}]